Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

idiopathic inflammatory myopathy - Clinical Profile, Genes & Research | Kisho | Kisho

Rare Disease

idiopathic inflammatory myopathy

MONDO:0600023

Also known as:idiopathic myositis

Find Clinical TrialsTrials

Overview

Idiopathic form of inflammatory myopathy.

TreatmentsNo approved treatments · 2 in pipeline

Clinical Trials48 registered · 26 recruiting

Diagnosis

Biomarker and diagnostic research for idiopathic inflammatory myopathy has been reported in the published literature.

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

No approved treatments are currently available for idiopathic inflammatory myopathy. An additional 2 compounds hold orphan drug designation.

Orphan Drug Designations

While no drugs are FDA-approved specifically for idiopathic inflammatory myopathy, some of the following designated compounds may be used off-label in clinical practice. Treatment decisions should be made in consultation with a specialist familiar with this condition.

The following drugs have received orphan drug designation from the FDA for idiopathic inflammatory myopathy. Orphan designation reflects regulatory interest and does not indicate approval for treatment.

Brand Name	Generic Name	Sponsor

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

48 clinical trials registered, 26 recruiting. Interventions under study include drug therapy, biologic therapy, other interventions, and medical devices. Pipeline includes 2 PHASE3, 8 PHASE2, 15 PHASE1. Research is sponsored by a mix of industry and academic institutions.

NCT ID	Title	Phase	Sponsor	Status
[NCT06925542](https://clinicaltrials.gov/study/NCT06925542)

Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 3:00 PM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

Questions for Your Care Team

→Are any of the 48 active clinical trials a good fit for my situation?
→What is the current development status of efgartigimod coformulated with recombinant human hyaluronidase PH20, and when might it become available?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

Research Type	Count	% of Total
Laboratory research	35	28%
Research summaries	25	20%
Disease patterns and progression	23	18%
Testing and diagnosis research	16	13%
Patient case studies	11	9%
Clinical study results	10	8%
New treatment approaches	7	6%

Kisho

idiopathic inflammatory myopathy

Overview

Diagnosis

Treatment

Orphan Drug Designations

Research Landscape

Medical References

Questions for Your Care Team

Questions for Your Care Team

Clinical Trials

Recent Publications

Latest News & Developments

Exploring the Autoimmune Spectrum of Combined Pulmonary Fibrosis and Emphysema: Inflammatory Myopathy Cases and a Systematic Review.

Clinical Characteristics and Malignancy Prevalence in Idiopathic Inflammatory Myopathies: A Single-Center Study from Southwestern Saudi Arabia.

Serum KL-6 and lung ultrasound B-lines: a combined non-invasive model for screening and predicting interstitial lung disease in idiopathic inflammatory myopathy.

MIHRA - Patient-Rooted Insights for Shaping Myositis Science (PRISMS)

idiopathic inflammatory myopathy

Overview

Diagnosis

Treatment

Orphan Drug Designations

Research Landscape

Medical References

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Clinical Trials

Recent Publications

Latest News & Developments

Exploring the Autoimmune Spectrum of Combined Pulmonary Fibrosis and Emphysema: Inflammatory Myopathy Cases and a Systematic Review.

Clinical Characteristics and Malignancy Prevalence in Idiopathic Inflammatory Myopathies: A Single-Center Study from Southwestern Saudi Arabia.

Serum KL-6 and lung ultrasound B-lines: a combined non-invasive model for screening and predicting interstitial lung disease in idiopathic inflammatory myopathy.

MIHRA - Patient-Rooted Insights for Shaping Myositis Science (PRISMS)